Navigation Links
Rock Creek Pharmaceuticals to Present at Biotech Showcase 2016
Date:12/10/2015

SARASOTA, Fla., Dec. 10, 2015 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (OTCQB: RCPI), a clinical stage, drug development company which is focused on the application of its lead compound to treat chronic inflammatory conditions, announced today that the Company will present at Biotech Showcase 2016 on Monday, January 11, 2016 at 10:00AM in the Powell Room, Third Floor, Park 55, Hilton Hotel in San Francisco, CA.

Michael Mullan, MBBS, Ph.D., Chairman and CEO of Rock Creek Pharmaceuticals, will present the Company's ongoing drug development initiatives, as well as updates to the company's corporate and regulatory strategy.

About Biotech Showcase 2016

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.

Biotech Showcase is organized by both Demy-Colton Life Science Advisors and the EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry. For more information and online registration please visit the EBD Group conference website: http://www.ebdgroup.com/bts/index.php

About Rock Creek Pharmaceuticals, Inc.:

Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases.

About Anatabine Citrate:

Rock Creek Pharmaceuticals' compound is a small molecule, cholinergic agonist that exhibits anti-inflammatory pharmacological characteristics, distinct from other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The Company's lead compound has been investigated extensively in pre-clinical (in vitro and in vivo) studies resulting in several peer reviewed and published scientific journal articles, covering models of multiple sclerosis, Alzheimer's disease, and autoimmune thyroiditis. All these studies demonstrated the anti-inflammatory effects of the Company's compound. In addition, the Company's compilation of human exposure, safety and tolerability data, has provided important insights for ongoing clinical and regulatory pharmaceutical development.

For more information, visit: http://www.rockcreekpharmaceuticals.com

Forward Looking Statements:

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, failure to obtain sufficient capital resources to fund our development program and operations, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our significant payables, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, pending litigation matters, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2014 filed on March 12, 2015. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

CONTACT:

Investor Contact: 
PCG Advisory Group 
Stephanie Prince 
646.762.4518 
sprince@pcgadvisory.com

Media Contact: 
PCG Advisory Group 
Sean Leous 
646 863 8998 
sleous@pcgadvisory.com

Company Contact: 
Rock Creek Pharmaceuticals, Inc.  
2040 Whitfield Ave. Suite 300 
Sarasota Florida, 34243 
1-844-727-0727 
IR@rockcreekpharma.com

Logo - http://photos.prnewswire.com/prnh/20150617/223737LOGO

 


'/>"/>
SOURCE Rock Creek Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Rock Creek Pharmaceuticals Announces the Addition of Key Opinion Leaders to Enhance Dermatological Disease Program
2. Rock Creek Pharmaceuticals Appoints New Director
3. Rock Creek Pharmaceuticals Announces European Patent
4. Creekridge Capital Reports Record Quarter 3 Bookings
5. Rock Creek Pharmaceuticals Announces Institutional Financing with Issuance of $20 Million of Convertible Notes
6. Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
7. Creekridge Capital Grows Sales Team
8. Rock Creek Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference
9. Rock Creek Pharmaceuticals Announces Targeting of Dermatological Disease, Updated Clinical and Regulatory Strategy and Second Quarter Results
10. Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells
11. Rock Creek Pharmaceuticals Announces Closing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2020)... ... February 10, 2020 , ... Aspire Regenerative, a ... to patients. , EMSculpt is an FDA-approved treatment designed to burn fat ... thighs, calves, biceps, and triceps. The EMSculpt machine utilizes HIFEM® (High-Intensity Focused Electromagnetic) ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... ... A. James, MS, RDN, has been selected as the chief of Nutrition and ... for all food service operations and clinical nutrition programs for the health care ...
(Date:2/10/2020)... ... 2020 , ... SentryHealth announced today the expansion ... clinics. Focused on leading innovation in the treatment of chronic disease, Healthstat will ... employee health clinics. Healthward delivers greater insight into eligibility for chronic care management ...
Breaking Medicine Technology:
(Date:2/10/2020)... ... February 10, 2020 , ... Buxton is ... company’s healthcare division. In this role, Nikki will support Buxton’s current and prospective ... healthcare product development. , “The healthcare industry is increasingly understanding the importance ...
(Date:2/10/2020)... , ... February 10, 2020 , ... ... has received 510(k) clearance for use with the Legacy™ and InterActive™ systems and ... combine ideal esthetics for your patients and more freedom of choice for your ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... ... management of chronic cardiometabolic conditions across populations, today announced its founder and chief ... HIMSS’ Most Influential Women in Health IT . Established in 2016, the ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... Real ... and the company that started a real food revolution in the medical community, is ... an extraordinary member of the feeding tube community each year during Feeding Tube ...
(Date:2/9/2020)... (PRWEB) , ... February 08, 2020 , ... Dr. Ezzat ... Dr. Nina Minagawa sent out a message to her professional network calling for support ... call. Both Moghazy and now RYM Director Dr. Minagawa have both been instrumental in ...
Breaking Medicine News(10 mins):